Prelude sells PersonalizeDx to Rosetta for $3.5mm in cash and stock
Rosetta Genomics Ltd. paid $2mm in cash and $1.5mm in stock (500k shares) to acquire private diagnostics company CynoGen Inc. (also known as PersonalizeDx) from Prelude Corp. As a form of payment, Rosetta will also provide Prelude with some assets and services.
- In Vitro Diagnostics
- Laboratory Testing Services
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Urine-based Testing
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.